Victoria Socha

DocwireNews

Researchers reported updated results from cohort A in the KEYNOTE-427 trial during a poster session at the ASCO 2019 Annual Meeting. KEYNOTE-427 is an open-label, single-arm, phase d2 study designed to examine efficacy and safety of first-line single-agent pembrolizumab in patients with clear cell renal cell carcinoma (ccRCC)&nbsp; (cohort A) and in patients with non&ndash;clear cell RCC (cohort B). Pembrolizumab is a programmed death 1 (PD-1) inhibitor.Scott S. Tykodi, MD<a href="https://www.fredhutch.org/en.html">,</a> and colleagues reported the updated results in a poster titled First-line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Results for KEYNOTE-427 cohort A.Patients in cohort A had histologically confirmed ccRCC, measured by RECIST v1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1), and no prior systemic therapy. Study participants received pembrolizumab 200 mg intravenously for 2 years or until confirmed progressive disease, unacceptable toxicity, or patient decision to withdraw.The primary end point of interest was objective response rate per RECIST v1.1 blinded independent central review. Secondary end points included duration of response, disease control rate, progression-free survival, overall survival, and safety.Median age of the 110 patients in cohort A was 64 years and median follow-up was 18.0 months. Among the 110 patients, 38.2% had favorable International Metastatic RCC Database Consortium (IMDC) risk, 47.3% had intermediate risk, and 14.5%^ had poor risk. Forty-seven point three percent were PD-L1 positive.Confirmed objective <a href="https://www.docwirenews.com/latest-nephrology-news/autoimmune-disorders-and-cpi-in-patients-with-rcc/">response rate</a> was 36.4% with three patients (2.7%) with complete response and 37 (33.6%) with partial response. Median duration of response was not reached; median progression-free survival was 7.1 months (95% confidence interval; 5.6%-11.0%); median overall survival was not reached.Among the patients with IMDC favorable risk (n=42), objective response rate was 31.0% (95% CI, 17.6%-47.1%); disease control rate was 61.9% (95% CI, 45.6%-76.4%); median duration of response was 13.7 months (95% CI, 4.2 months-18.0 months); and duration of response &ge;6 months among responders was 68.4%. Among those with intermediate/poor IMDC risk, the values were 39.7% (28.0%-52.3%); 54.4% (41.9%-66.5%); not reached; and 80.9%, respectively.As measured by PD-L1 status, confirmed objective response rate was 44.2% and 29l.3% for positive and negative, respectively. By sarcomatoid differentiation (n=11), confirmed objective response rate was 63.6%.Treatment-related adverse events occurred in 80.9% of patients; pruritus and fatigue were the most commonly reported AEs (28.2% for both). One patient died of treatment-related pneumonitis.In conclusion, the researchers said, &ldquo;With a median 18 months follow-up, first-line pembro monotherapy continued to show antitumor activity in patients with ccRCC. Meaningful responses were observed in patients with intermediate/poor IMDC risk, PD-L1 positive, and sacromotoid differentiated tumors. Safety profile was comparable to previously reported.&rdquo;Clinical trial information: NCT02853344Source: Tykodi SS, Donskov F, Lee J-L; et al. First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A. Abstract of a poster presented at the American Society of Clinical Oncology 2019 Annual Meeting, June 3, 2019, Chicago, Illinois.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

KEYNOTE-427 Updated Results from Cohort A

ASCO 2019

Researchers reported updated results from cohort A in the KEYNOTE-427 trial during a poster session at the ASCO 2019 Annual Meeting. KEYNOTE-427 is an open-label, single-arm, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe